StoxKwality Pharmaceuticals Limited
NSE: KPL · Unclassified
Ask the data
Instant answers about Kwality Pharmaceuticals Limited — computed from its filings, no language modelPrice & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY23† | FY24† | FY25† | FY26† | |
|---|---|---|---|---|
| Revenue | 251.0 | 307.2 | 370.2 | 503.1 |
| EBITDA | 60.3 | 66.6 | 80.5 | 118.2 |
| Operating margin | 24.0% | 21.7% | 21.7% | 23.5% |
| Interest | 6.0 | 10.4 | 9.9 | 11.0 |
| Depreciation | 14.9 | 19.5 | 18.3 | 19.8 |
| Profit before tax | 25.8 | 31.5 | 54.2 | 89.5 |
| Tax | 6.3 | 7.6 | 14.3 | 22.1 |
| Net profit | 19.5 | 23.9 | 39.9 | 67.3 |
Quarterly performance
last 17 quarters · ₹ crore| JUN '22† | SEP '22† | DEC '22† | MAR '23† | JUN '23† | SEP '23† | DEC '23† | MAR '24† | JUN '24† | SEP '24† | DEC '24† | MAR '25† | JUN '25† | SEP '25† | DEC '25† | MAR '26† | JUN '26† | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.2 | 56.0 | 56.0 | 68.8 | 67.5 | 69.7 | 78.1 | 92.0 | 80.1 | 90.0 | 84.4 | 115.7 | 111.5 | 111.3 | 123.5 | 156.8 | 162.3 |
| Operating profit | 18.0 | 15.6 | 15.2 | 11.5 | 13.8 | 15.3 | 16.7 | 20.9 | 17.4 | 19.7 | 17.5 | 25.9 | 24.2 | 25.4 | 29.9 | 38.7 | 41.0 |
| Operating margin | 25.7% | 27.8% | 27.1% | 16.7% | 20.5% | 21.9% | 21.4% | 22.7% | 21.7% | 21.9% | 20.7% | 22.4% | 21.7% | 22.8% | 24.3% | 24.7% | 25.3% |
| Other income | 0.4 | 0.8 | 0.3 | 1.5 | 0.4 | 0.2 | 0.6 | 0.6 | 0.3 | 0.2 | 0.7 | 0.8 | 0.4 | 0.9 | 0.5 | 1.1 | 0.6 |
| Interest | 1.2 | 1.2 | 1.9 | 1.7 | 2.2 | 2.4 | 2.7 | 3.1 | 2.5 | 2.7 | 2.2 | 2.5 | 2.8 | 2.8 | 2.5 | 2.9 | 2.7 |
| Depreciation | 3.1 | 3.8 | 3.5 | 4.4 | 4.8 | 4.9 | 4.8 | 5.0 | 4.0 | 4.6 | 4.5 | 5.1 | 4.8 | 5.0 | 4.8 | 5.3 | 5.0 |
| Profit before tax | 14.1 | 11.3 | 10.0 | -9.6 | 7.2 | 8.2 | 9.8 | 6.2 | 11.1 | 12.6 | 11.4 | 19.1 | 17.0 | 18.4 | 22.4 | 31.6 | 34.0 |
| Tax | 3.5 | 2.3 | 2.8 | -2.3 | 1.8 | 1.9 | 2.1 | 1.8 | 2.8 | 4.1 | 2.9 | 4.6 | 5.1 | 4.3 | 6.3 | 6.4 | 8.4 |
| Net profit | 10.6 | 9.1 | 7.2 | -7.4 | 5.5 | 6.3 | 7.7 | 4.5 | 8.4 | 8.5 | 8.5 | 14.5 | 11.9 | 14.1 | 16.0 | 25.3 | 25.6 |
| EPS ₹ | 10.05 | 8.52 | 6.92 | -7.15 | 5.17 | 6.03 | 7.42 | 4.33 | 8.06 | 8.18 | 8.23 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue YoY | — | — | — | — | -3.9% | 24.5% | 39.4% | 33.7% | 18.7% | 29.3% | 8.1% | 25.8% | 39.2% | 23.6% | 46.3% | 35.6% | 45.6% |
| Profit YoY | — | — | — | — | -48.3% | -30.8% | 6.5% | — | 53.6% | 35.5% | 10.9% | 222.2% | 42.5% | 66.5% | 87.5% | 74.4% | 114.8% |
Returns & margins
trailing-twelve-month, per quarter| MAR '23 | JUN '23 | SEP '23 | DEC '23 | MAR '24 | JUN '24 | SEP '24 | DEC '24 | MAR '25 | JUN '25 | SEP '25 | DEC '25 | MAR '26 | JUN '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net margin | 7.8% | 5.8% | 4.4% | 4.2% | 7.8% | 8.4% | 8.5% | 8.6% | 10.8% | 10.8% | 11.6% | 12.2% | 13.4% | 14.6% |
| EBITDA margin | 24.0% | 22.6% | 21.3% | 20.2% | 21.7% | 21.9% | 21.9% | 21.8% | 21.7% | 21.7% | 22.0% | 22.8% | 23.5% | 24.4% |
| Interest coverage | 5.28 | 3.71 | 2.93 | 2.73 | 4.03 | 4.31 | 4.62 | 4.96 | 6.49 | 6.92 | 7.41 | 8.28 | 9.16 | 10.79 |
Balance sheet
equity vs borrowings over time · ₹ croreNot filed yet.
Cash flow
annual · ₹ crore · line = free cash flowNot filed yet.
Where the assets sit
No balance sheet filed yet.
Peer comparison
largest in Unclassified · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Avantel Limited | 36,86,04,549 | 138.69 | — | 1059360.68 | 0.0% |
| Ducol Organics And Colours Limited | 19,55,275 | 120.00 | — | 20089.13 | 0.0% |
| Jio Platforms Limited | 12,57,181 | 1,406.40 | — | 3.57 | — |
| SBI Funds Management Limited | 1,01,750 | 499.55 | — | — | — |
| Tamilnadu Telecommunication Limited | 91,314 | 9.93 | — | — | — |
| Manipal Health Enterprises Limited | 76,294 | 646.70 | — | — | — |
| INDO-MIM Limited | 59,042 | 1,219.50 | — | — | — |
| AvenuesAI Limited | 45,138 | 129.25 | 153.6 | 9.51 | 6.2% |
| Dhoot Transmission Limited | 32,761 | 1,601.60 | — | 8.11 | — |
| 3M India Limited | 31,071 | 27,570.00 | 53.8 | 17.57 | 32.7% |
| Kwality Pharmaceuticals Limited | — | 3,644.80 | — | — | — |
StoxGud checklist: Neutral setup · 4/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
FAQs
What is the share price of Kwality Pharmaceuticals Limited?
Kwality Pharmaceuticals Limited (KPL) closed at ₹3,644.80 on NSE on 06 Nov 2026.
How fast is Kwality Pharmaceuticals Limited growing?
Kwality Pharmaceuticals Limited: revenue has compounded at 26.1% a year over three years; net profit at 51.2% a year. Latest-quarter revenue is up 45.6% year on year, profit up 114.8%.
How profitable is Kwality Pharmaceuticals Limited?
On a trailing-twelve-month basis operating margin 24.4%, net margin 14.6%.
How much debt does Kwality Pharmaceuticals Limited have?
Debt to equity isn't meaningful for Kwality Pharmaceuticals Limited (banks borrow as part of their business) or isn't filed yet.
Kwality Pharmaceuticals Limited's results are not in NSE's XBRL filings, so these are its standalone quarterly results as published on BSE (†), ₹ crore, from JUN '22; full years are summed from the quarters. No balance sheet or cash flow is available from this source. Information only, not investment advice.